Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 511 to 520 of 860 total matches.

Exemestane For Advanced Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2000  (Issue 1076)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
The FDA has approved exemestane, an aromatase inhibitor, for the treatment of postmenopausal women with advanced breast cancer that has progressed during treatment with tamoxifen.
Med Lett Drugs Ther. 2000 Apr 17;42(1076):35-6 |  Show IntroductionHide Introduction

Ciclopirox (Penlac) Nail Lacquer for Onychomycosis

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2000  (Issue 1080)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Richard Kim, M.D ...
Ciclopirox nail lacquer (Penlac - Dermik) has been approved by the FDA for treatment of mild-to-moderate onychomycosis due to Trichophyton rubrum, without involvement of the lunula. The drug has been available for many years as a lotion and cream (Loprox) for treatment of cutaneous fungal infection
Med Lett Drugs Ther. 2000 Jun 12;42(1080):51-2 |  Show IntroductionHide Introduction

Photodynamic Therapy With Verteporfin (Visudyne) For Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2000  (Issue 1086)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew ...
Photodynamic therapy with verteporfin (Visudyne--CIVA Vision), an injectable drug, is now being used for treatment of age-related macular degeneration. The drug is a benzoporphyrin derivative that, when activated by light in the presence of oxygen, generates highly reactive radicals that damage neovascular endorthelium and occlude the vessels.
Med Lett Drugs Ther. 2000 Sep 4;42(1086):81-2 |  Show IntroductionHide Introduction

Rivastigmine (Exelon) For Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
Rivastigmine tartrate (Exelon - Novartis), a carbamate-based cholinesterase inhibitor, is now being marketed for treatment of patients with dementia due to Alzheimer's disease.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):93-4 |  Show IntroductionHide Introduction

Automated External Defibrillators

   
The Medical Letter on Drugs and Therapeutics • Dec 11, 2000  (Issue 1094)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
Recent studies suggest that timely use of automated external defibrillators operated by laypersons with minimal training can save lives. Purchase of these devices for public places or home use requires authorization from a physician.
Med Lett Drugs Ther. 2000 Dec 11;42(1094):116 |  Show IntroductionHide Introduction

Fluoxetine Sarafem For Premenstrual Dysphoric Disorder

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001  (Issue 1096)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) previously sold only as Prozac, is now also marketed as Sarafem for treatment of premenstrual dysphoric disorder (PMDD). Generic fluoxetine is expected to be available sometime this year.
Med Lett Drugs Ther. 2001 Jan 22;43(1096):5-6 |  Show IntroductionHide Introduction

A Progestin-Releasing Intrauterine Device For Long-Term Contraception

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001  (Issue 1096)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
The FDA had approved an intrauterine contraceptive device that releases the synthetic progestin levonorgestrel over a period of five years. The device has been available in Europe for 10 years.
Med Lett Drugs Ther. 2001 Jan 22;43(1096):7-8 |  Show IntroductionHide Introduction

Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2001  (Issue 1098)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein thrombosis.
Med Lett Drugs Ther. 2001 Feb 19;43(1098):14-5 |  Show IntroductionHide Introduction

Galantamine (Reminyl) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001  (Issue 1107)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Galantamine hydrobromide (Reminyl), a tertiary alkaloid and phenanthrene derivative extracted from daffodil bulbs, is now being marketed for oral treatment of mild to moderate Alzheimer's disease. Galantamine is the fourth acetylcholinesterase inhibitor approved for this indication.
Med Lett Drugs Ther. 2001 Jun 25;43(1107):53-4 |  Show IntroductionHide Introduction

Private Cord Blood Banks

   
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004  (Issue 1178)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Private cord blood banks continue to advertise their services to couples expecting a child. Cord blood can be stored safely for many years. Public cord blood banks accept collections only from affiliated hospitals (Medical Letter 2001; 43:84). Units are available for any patient; there is no guarantee that a particular donor's blood will be available if the donor or a family member needs a stem cell transplant. Many patients can find an unrelated match in a public cord blood bank, but members of minority ethnic groups are often more difficult to match (www.marrow.org). Private cord blood banks...
Med Lett Drugs Ther. 2004 Mar 15;46(1178):21-2 |  Show IntroductionHide Introduction